Efficacy did not appear to differ between countries.Treatment with tolterodine resulted in significantly greater mean reductions in both the incontinence impact domain (Dry mouth was the most common adverse event, occurring in over half of patients in the oxybutynin, a third in the tolterodine and only 10% of the placebo group (More patients were withdrawn because of adverse events from the oxybutynin group than from the other two groups (In all, 15 patients reported serious adverse events (tolterodine eight, oxybutynin seven) but only one of these was considered possibly related to treatment (cardiac failure in a patient treated with oxybutynin).
After 12 weeks of treatment, the proportion of patients who perceived an improvement in their bladder condition was greater in the tolterodine (72%) and oxybutynin (73%) groups than in the placebo group (59%). In a recent large‐scale epidemiological survey in 11 Asian countries, 53% of women and 45% of men reported symptoms of OAB [This was a randomized, double‐blind, placebo‐ and active comparator‐controlled trial conducted at 69 centres in Japan (57) and Korea (12). D. Getsios; J.J. Caro; K.J. Patients in Korea reported fewer adverse events overall, fewer serious adverse events and fewer types of adverse event than did patients in Japan. You must declare any conflicts of interest related to your comments and responses. Efficacy assessments included changes from baseline in numbers of incontinence episodes per week, voids/24 h and mean volume voided/void.
and you may need to create a new Wiley Online Library account.Enter your email address below and we will send you your usernameIf the address matches an existing account you will receive an email with instructions to retrieve your username Department of Urology, Tokyo University, Tokyo, Japan,Department of Urology, Tokyo University, Tokyo, Japan,Department of Urology, College of Medicine, Seoul National University,Department of Urology, College of Medicine, Korea University Anam Hospital Seoul, Korea, and ‡Tokyo Teishin Hospital, JapanDepartment of Urology, Tokyo University, Tokyo, Japan,Department of Urology, Tokyo University, Tokyo, Japan,Department of Urology, Tokyo University, Tokyo, Japan,Department of Urology, College of Medicine, Seoul National University,Department of Urology, College of Medicine, Korea University Anam Hospital Seoul, Korea, and ‡Tokyo Teishin Hospital, JapanDepartment of Urology, Tokyo University, Tokyo, Japan,Use the link below to share a full-text version of this article with your friends and colleagues.
Accordingly the ANDA is approved. * If you log out, you will be required to enter your username and password the next time you visit. All material on this website is protected by copyright, Copyright © 1994-2020 by WebMD LLC. Many of the medications we take for our disorders come in immediate release or extended release forms. Please enter a Recipient Address and/or check the Send me a copy checkbox. 82 Parent 64 Met.
Almost three‐quarters of patients (72%) perceived an improvement in their bladder condition after 12 weeks of treatment with tolterodine, compared with 59% with placebo; this was nearly significant (Tolterodine was better tolerated than oxybutynin in the present study, with a lower overall incidence of adverse events.
The low incidence of urinary retention with tolterodine is consistent with that reported in Caucasian populations and indicates similar safety in Asian patients. Commenting is limited to medical professionals. The study was not designed to detect treatment differences within country‐specific subgroups, but the greater efficacy of tolterodine than oxybutynin produced statistically significant differences, primarily in the Japanese population.